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Abstract
Background
Acute liver failure (ALF) has been reported in ornithine transcarbamylase deficiency
(OTCD) and other urea cycle disorders (UCD). The frequency of ALF in OTCD is not well-
defined and the pathogenesis is not known.
Aim
To evaluate the prevalence of ALF in OTCD, we analyzed the Swiss patient cohort. Labora-
tory data from 37 individuals, 27 females and 10 males, diagnosed between 12/1991 and
03/2015, were reviewed for evidence of ALF. In parallel, we performed cell culture studies
using human primary hepatocytes from a single patient treated with ammonium chloride in
order to investigate the inhibitory potential of ammonia on hepatic protein synthesis.
Results
More than 50% of Swiss patients with OTCD had liver involvement with ALF at least once in
the course of disease. Elevated levels of ammonia often correlated with (laboratory) coagu-
lopathy as reflected by increased values for international normalized ratio (INR) and low lev-
els of hepatic coagulation factors which did not respond to vitamin K. In contrast, liver
transaminases remained normal in several cases despite massive hyperammonemia and
liver involvement as assessed by pathological INR values. In our in vitro studies, treatment
of human primary hepatocytes with ammonium chloride for 48 hours resulted in a reduction
of albumin synthesis and secretion by approximately 40%.
Conclusion
In conclusion, ALF is a common complication of OTCD, which may not always lead to
severe symptoms and may therefore be underdiagnosed. Cell culture experiments suggest
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an ammonia-induced inhibition of hepatic protein synthesis, thus providing a possible
pathophysiological explanation for hyperammonemia-associated ALF.
Introduction
Patients with inherited defects in the urea cycle (Fig 1) are at risk of recurrent acute metabolic
crises with life-threatening hyperammonemia, associated with acute or chronic brain damage
leading to severe neurological long-term disabilities, impairing quality of life and leading to sig-
nificant mortality [1–4]. The main trigger for metabolic crises is an imbalance between a
reduced caloric uptake and an increased caloric demand causing protein catabolism and hence
provoking hyperammonemia.
In addition to neurological complications, patients with acute hyperammonemia may suffer
from recurrent episodes of acute liver failure (recurrent ALF, RALF) with associated coagulo-
pathy [5–9]. In the largest hitherto published study, reporting 89 individuals with ornithine
transcarbamylase deficiency (OTCD,MIM #311250) evaluated at two large metabolic centers
(Children`s Hospital Colorado and the University of California, Los Angeles Medical Center),
57% of 49 symptomatic patients had liver involvement (liver injury as determined by elevated
Fig 1. Urea cycle. In the urea cycle the “toxin” ammonium (NH4
+) is converted to non-toxic urea by five consecutive enzymatic reactions in the liver. In
hepatocytes, the rate-limiting, ATP-dependent enzyme carbamoyl phosphate synthetase 1 (CPS1), which is allosterically activated by N-acetyl glutamate
(NAG), produced by N-acetyl glutamate synthase (NAGS), not shown, and ornithine transcarbamylase (OTC) are located in the mitochondria, while
argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL) and arginase (ARG) are in the cytoplasm. Inherited defects in any of these enzymes can
cause recurrent episodes of hyperammonemia. Defects in two mitochondrial transporters, not shown, may also result in hyperammonemia.
doi:10.1371/journal.pone.0153358.g001
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liver transaminases and/or ALF as determined by pathological coagulation parameters) [6].
However, the pathophysiology of this complication is poorly understood [3, 6, 10, 11].
In severe cases, ALF may require urgent liver transplantation, which is essentially curative
of OTCD, however, there are several limitations including liver organ shortage, short and long-
term morbidity and mortality including lifelong immunosuppressive therapy with major asso-
ciated complications. In neonates, urgent liver transplantation is often not a feasible therapeu-
tic option due to practical restrictions associated with small size.
In ALF associated with metabolic diseases, there is a lack of consensus criteria for liver trans-
plantation [12]. Some UCD patients have undergone liver transplantation due to the severe
impairment of liver function during their first metabolic crisis, and before the diagnosis was
definitively confirmed [9]. However, other patients completely recovered despite a similar sever-
ity of liver failure [13, 14]. It was thus suggested that before liver transplantation is performed in
patients with ALF of unknown cause, results of a full metabolic screening should be awaited [5, 8,
15]. Liver histology does not help to stratify patients, as it was grossly unremarkable in UCD
patients suffering from ALF, only occasionally displaying subtle structural changes even in older
patients [16]. Thus, the clinical and histological manifestation of liver disease in UCD patients is
distinct from patients with chronic hepatitis, chronic liver failure or cirrhosis. ALF is also
observed in patients with other metabolic diseases, for instance in pyruvate dehydrogenase
(PDH) complex deficiency [17], which can present with secondary hyperammonemia.
The role of ammonia toxicity in contributing to the development of ALF was recently
emphasised [18]. In contrast to adult patients with e.g. liver cirrhosis, in which elevated ammo-
nia levels are the consequence of (chronic) liver failure, we hypothesise that hyperammonemia
is a relevant trigger of ALF in UCD patients.
To substantiate this hypothesis, we analysed events of ALF in the Swiss OTCD patient cohort.
In addition, we exposed human primary hepatocytes to ammonium chloride (NH4Cl) to find evi-
dence for a causative role of hyperammonemia in impairing hepatic protein synthesis.
Methods and Materials
Study cohort
For the present study, we analysed the Swiss cohort of OTCD patients. All subjects were diag-
nosed and treated between 12/1991 and 03/2015 in a Swiss metabolic center. Vitamin K was
not administered systematically, however some patients received it according to their coagula-
tion status based on the decision of the treating center. The majority of patients was enrolled in
the National Institutes of Health (NIH)-funded, multi-site Longitudinal Study of the Urea
Cycle Disorders Consortium (UCDC) [19, 20] in which the University Children`s Hospital
Zurich has been a partner since 09/2008. Written informed consent was obtained from each
patient or their legal guardian(s), and the responsible ethics committee approved this natural
history study (Kantonale Ethikkommission; StV 39/07).
Clinical and laboratory data collection
From each subject with (biochemically or molecular genetically) confirmed OTCD, a detailed
medical history was taken including family history, age and clinical symptoms at presentation
and at diagnosis, and all available medical records and laboratory data from the past were
obtained for review. Patients are usually seen twice a year (adults only once a year) for regular
study visits. These include a detailed history of metabolic decompensations and hospitalizations,
as well as a physical examination and laboratory evaluation. According to the study protocol, lab-
oratory values to assess metabolic status (plasma ammonia, plasma amino acid profile and uri-
nary orotic acid), liver function (various liver parameters including aspartate aminotransferase
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(ASAT), alanine aminotransferase (ALAT) and albumin) and coagulation (INR/prothrombin
time (PT)/Quick percentage value, activated partial thromboplastin time (aPTT) and fibrinogen)
were taken. Response to vitamin K was evaluated in some of the patients. From patients who suf-
fered from RALF, either the crisis with the most pathological INR/PT or Quick percentage value
was chosen or a representative episode where most of the laboratory values were available.
For this study, we used a simple definition of ALF, which is, however, based on and in full
agreement with the one used by the “Pediatric Acute Liver Failure Study Group” in which an
INR1.5 together with clinical signs of encephalopathy is considered sufficient to define ALF
[21, 22]. Thus, since all of our patients with an INR1.5 showed some neurological signs
(although in very rare cases only soft clinical signs and not distinguishable whether chronic or
related to the acute situation), we did not add any further criteria to define ALF (e.g. biochemi-
cal evidence of acute liver injury). In a few cases for which no INR values were available, we
analysed Quick percentage values or PT.
Culture and NH4Cl treatment of primary human hepatocytes
Primary human hepatocytes were isolated from resected liver tissue from a non-affected
(regarding OTCD) male patient undergoing liver surgery after having obtained informed con-
sent. Hepatocytes were cultured according to an established standard procedure [23] and
6.0x104 cells/cm2 were seeded on collagen-coated plastic dishes (96-well-plates for cell viability
assays and 60 mm dishes for all other experiments) prior to culture in Dulbecco`s minimum
essential medium (DMEM) supplemented with 10% fetal bovine serum, 50 U/mL penicillin,
50 μg/mL streptomycin, and 1 μmol/L dexamethasone. After overnight culture, the medium
was replaced by serum-free Williams E medium1glutaMax™, which contains the dipeptide L-
alanyl-L-glutamine, a more stable form of L-glutamine, thus preventing its deamination and
additional (unwanted) release of ammonia. Twenty-four hours after serum deprivation, hepa-
tocytes were treated with different concentrations of NH4Cl (0, 0.1, 1 and 10 mmol/L) for 24
and 48 hours in the same serum-free Williams E medium1glutaMax™.
Cell viability assay
After 24 and 48 hours of NH4Cl treatment, cell viability was assessed by [3-(4,5-dimethyl-thia-
zol-2-yl) 2,5-diphenyltetrazolium bromide] MTT assay (Life Technologies™) according to the
manufacturer`s protocol.
Albumin quantification
After 24 and 48 hours of NH4Cl treatment, cell culture supernatant was collected in an Eppen-
dorf tube and centrifuged at 10`000 g for 5 minutes. Supernatant was then transferred to a
fresh Eppendorf tube and stored at -80°C until analysis. Albumin production and secretion
was quantified by ELISA (Bethyl Laboratories Inc.) according to the manufacturer`s protocol.
Quantification of urea and ASAT
Supernatant samples were also used for the quantification of urea production. Urea was quanti-
fied by cation exchange chromatography using the Biochrom 30+ Amino Acid Analysis System
(Analytical1 Technologies Limited) according to the manufacturer`s protocol.
The same supernatant samples were further analyzed for the quantification of ASAT levels
which were determined in the routine clinical chemistry laboratory with the Beckman Coulter
Synchron1 System according to the manufacturer`s protocol.
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Statistical analysis
All statistics were performed applying Graphpad Prism 6 software. For statistical analysis of
cell culture studies Student’s T-test was applied and p< 0.05 considered significant. Correla-
tion studies between plasma ammonia levels and INR values in patients were performed by cal-
culating the Pearson`s correlation coefficient and significance was tested by the two-tailed test
and p< 0.05 considered as significant. For this purpose only patients with at least 5 simulta-
neously obtained ammonia and INR values were included.
Results
Study cohort
The characteristics of the Swiss OTCD cohort are listed in Table 1. The 37 patients (age 4–50
years in September 2015) derive from 21 families. Of 27 females (mean age at diagnosis 17.5
years, range 10 months-41 years), 19 are symptomatic (including two deaths during the initial
metabolic crisis), five are asymptomatic, and information is lacking from three patients. From
the ten male patients (mean age at diagnosis 4 months, range 3 days-24 months), seven suf-
fered from a neonatal onset of disease that was fatal in five patients. Two males (No. 4.1 and
6.1) received liver transplantation at the ages of 4 and 15 years, respectively.
All 21 index patients were diagnosed by selective screening, and 16 patients were diagnosed
due to affected family members (two patients were diagnosed prenatally).
Mutational analysis in our cohort revealed 14 differentOTCmutations of which four are novel
changes. In three females, no mutation was found and diagnosis was based on the typical biochemi-
cal profile including orotic aciduria. The most prevalent mutation in our cohort, the well-character-
ized change c.386G>A; p.Arg129His [34, 35], was found in seven patients from three families.
Acute liver failure in study cohort
Of the 37 patients, 29 could be analyzed regarding ALF (Fig 2) (9 males and 20 females), while
one male and seven female cases were excluded from all further studies due to a lack of clinical
and/or laboratory data (missing medical reports and no values for coagulation tests). 6/9 male
patients had a neonatal onset of OTCD with ALF. 4/6 neonatal male patients deceased during
the initial crisis, and the two who survived the neonatal period experienced RALF. All late
onset male patients suffered from ALF (RALF in 2/3 and a single episode in 1/3). Thus, all nine
male patients suffered from ALF that was recurrent in 4/5 alive patients.
15/20 females were symptomatic, of whom six had documented episodes of ALF (recurrent
in 2/6). None of the five asymptomatic females experienced ALF. Thus, 40% of the symptom-
atic females suffered at least once from ALF. In the entire cohort, 15/29 cases suffered from
ALF (52%), and 6/29 (21%) from recurrent episodes. In none of the patients, there was any evi-
dence for a viral infection or other concomitant illness as cause of elevated transaminases, and
testing for viruses remained negative although this was not performed systematically.
Ammonia, coagulation, response to vitamin K and liver function tests in
patients
Table 2 shows laboratory data of the 15 patients with ALF that was present already at the initial
crisis when the diagnosis of OTCD was made (except patient 14.2 who was diagnosed due to
her affected brother).
In patients suffering from ALF, INR values ranged from 1.5 to 4.8 (normal< 1.2), Quick
values from 6 to 47% (normal> 70), and ammonia levels from 37 to 1821 μmol/L (normal 12–
48; in the neonatal period< 100).
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Table 1. Summary of the Swiss cohort of OTC deficient patients.
No.a Sexb Age at Diagnosisc Current Aged Symptomse Mutation (NM_000531.5)f Referencesg
1 f 18 m 25 y yes no mutation found
2 f 2 y 24 y yes c.421C>T; p.Arg141* [24]
3 f 19 m 20 y yes no mutation found
4.1 m 2 m 17 y yes c.540G>C; p.Gln180His [25]
4.2 f 33 y 46 y no c.540G>C; p.Gln180His
4.3 f 15 y 28 y no c.540G>C; p.Gln180His
5 f 13 y 30 y yes c.533C>T; p.Thr178Met [26]
6.1 m 7 d 16 y yes c.386G>A; p.Arg129His [27]
6.2 f 34 y 50 y no c.386G>A; p.Arg129His
7.1 f 24 y 38 y yes c.506C>A; p.Pro169His this study
7.2 f prenatal 7 y yes c.506C>A; p.Pro169His
8.1 m 7 d † death c.717G>A; p.Glu239 = [28]
8.2 f 34 y 48 y yes c.717G>A; p.Glu239 =
9 f 10 m 12 y yes no mutation found
10 f 7 y 18 y yes c.583G>A; p.Gly195Arg [29]
11 f 20 m 10 y yes c.674C>T; p.Pro225Leu [30]
12 f 8 y 17 y yes c.422G>A; p.Arg141Gln [31]
13.1 f 16 y † death c.538C>T; p.Gln180* this study
13.2 f 38 y 38 y yes c.538C>T; p.Gln180*
13.3 f n.a. n.a. n.a. c.538C>T; p.Gln180*
13.4 f n.a. n.a. n.a. c.538C>T; p.Gln180*
13.5 f n.a. n.a. n.a. c.538C>T; p.Gln180*
13.6 m prenatal † death c.538C>T; p.Gln180*
14.1 m 9 d 8 y yes c.386G>A; p.Arg129His [27]
14.2 f 3 y 11 y yes c.386G>A; p.Arg129His
14.3 f 41 y 50 y no c.386G>A; p.Arg129His
15 f 6 y † death c.274C>T; p.Arg92* [32]
16.1 m 11 m 6 y yes c.386G>A; p.Arg129His [27]
16.2 f 31 y 36 y no c.386G>A; p.Arg129His
17.1 m 4 d † death c.584G>C; p.Gly195Ala this study
17.2 f 26 y 31 y yes c.584G>C; p.Gly195Ala
18 m 3 d † death c.548A>G; p.Tyr183Cys [33]
19.1 m 2 y 4 y yes c.860C>T; p.Thr287Ile this study
19.2 f 36 y 38 y yes c.860C>T; p.Thr287Ile
20 f 2 y 4 y yes c.274C>T; p.Arg92* [32]
21.1 m 3 d † death c.674C>T; p.Pro225Leu [30]
21.2 f 28 y 29 y yes c.674C>T; p.Pro225Leu
aNo., case number, in families with more than one case, x.1 stands for the index case which was diagnosed by selective screening in all 21 families
bSex; f, female; m, male
cAge at diagnosis (in most cases diagnosis was ﬁrst established biochemically and later conﬁrmed by mutational analysis) and
dCurrent age (as of September 2015); d, days, m, months, y, years
†, deceased; n.a., not available
eSymptoms; no = no symptoms; yes = any symptoms from mild to severe; death = deceased due to (complications of) OTCD
fMutations are indicated by changes in the coding DNA (c.) and protein (p.) reference sequences (NM_000531.5 and NP_000522.3, respectively)
following the Human Genome Variation Society nomenclature.
gPreviously described mutations are cited in the reference list, four mutations are novel.
doi:10.1371/journal.pone.0153358.t001
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Correlation studies provided strong evidence for a positive correlation between plasma
ammonia levels and INR values in the patient cohort suffering from ALF (n = 11 [cases No. 1;
3; 4.1; 6.1; 9; 11; 14.1; 14.2; 16.1; 19.1 and 20] as expressed by a Pearson coefficient ranging
from 0.12 to 0.99 with a median of 0.76, which was significant in 6/11 patients. In contrast, in
patients not affected by ALF (n = 7 [cases No. 2; 6.2; 7.1; 8.2; 10; 12 and 16.2], there was no sig-
nificant correlation between plasma ammonia levels and INR values in any of these patients
and Pearson coefficient ranged from -0.53 to 0.85 with a median of 0.06. The positive correla-
tion of hyperammonemia and elevated INR values in patients with ALF is exemplified for
patient 20 (Table 3) who suffered from two episodes of ALF within 2 months.
From our entire patient cohort, only siblings 14.1 and 14.2, both had pathological INR val-
ues in the presence of only mildly elevated or even normal plasma ammonia levels and both
displayed only mild neurological symptoms compatible with a remission state of disease on
several routine outpatient controls. In all other patients, pathological INR values exclusively
occurred during hyperammonemia. In several patients, thorough analysis of individual pro-
Fig 2. Overview of included patients and occurrence of acute liver failure. From 37 cases, 29 were eligible for further studies regarding occurrence of
acute liver failure (ALF). Male patients are shown as neonatal (onset in the first month of life) and late onset (symptoms beyond the first month of life) cases.
Females are classified as symptomatic or asymptomatic. The bottom boxes indicate the occurrence of ALF.
doi:10.1371/journal.pone.0153358.g002
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and anticoagulant factors were performed, revealing reduced functional levels of the vitamin
K-dependent factors (FII, VII, IX, X, protein C and S) as well as reduced levels of the non-vita-
min K-dependent factor V (as depicted in Table 4 for patient 14.1). As anticipated, neither the
oral application of 5 mg vitamin K, nor an additional intravenous (i.v.) dose of 5 mg vitamin K
led to an increase of the vitamin-K-dependent factors, thus virtually excluding a vitamin K
deficiency (Table 4). Hemostatic factors with the shortest plasma half-lives such as factor VII
(5 hours) and protein C (7 hours) showed the most pronounced reduction of plasma levels,
whereas e.g. factor II with a half-life of 65 hours remained in the subnormal or low normal
range. Although not systematically assessed in our patient cohort, in none of the patients we
observed a response to vitamin K.
Table 2. Laboratory values of OTCD patients suffering from acute liver failure.
No. Sex RALFa INR Ref.
<1.2
Quick (%) Ref.
>70
Albumin (g/L) Ref.
34–42
Ammonia (μmol/L) Ref.
12–48
ALAT (U/L) Ref.
<33
ASAT (U/L) Ref.
<50
1 f no n.a. 15 n.a. 235 1900 2900
3 f no 4.8 13 40 207 1615 1148
4.1 m yes 2.7 n.a. n.a. n.a. n.a. n.a.
6.1 m yes 2.5 31 34 868 35 25
8.1 m n/a 2.2 34 n.a. 2390 23 86
9 f no 1.5 47 45 325 95 54
11 f no n.a.b n.a.b n.a. 300 1278 411
14.1 m yes 2.2 30 36 73 33 46
14.2 f yes 1.7 39 35 37 19 35
16.1 m no 1.5 43 n.a. 276 152 57
17.1 m n/a n.a. 6 n.a. 708 n.a. n.a.
18 m n/a 2.4 32 31 1821 32 82
19.1 m yes n.a. 20 n.a. 114 2837 1986
20 f yes 4.2 16 28 354 739 867
21.1 m n/a 3.0 23 n.a. 1650 13 56
aRALF, recurrent episodes of acute liver failure; n/a = not applicable, because these patients deceased during the ﬁrst metabolic crisis in the neonatal
period and thus could not experience RALF
bIn this patient neither value for INR nor Quick was available, however, a highly pathological value for the prothrombin time
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; Ref., reference level
doi:10.1371/journal.pone.0153358.t002
Table 3. Association of coagulopathy and acute liver failure with hyperammonemia.
Laboratory parameters INR Quick (%) aPTTa (sec.) Clotting
factors (%)
Albumin (g/L) Ammonia (μmol/L)
Vb VIIb
Normal Range <1.2 >70 <40 >70 >60 34–42 12–48
At diagnosis 2.3 30 42 43 14 30 498
In remission state 0.9 >110 n.d. 131 115 33 40
At metabolic crisis 4.2 16 55 24 2 28 354
Table 3 illustrates two episodes of acute liver failure, which occurred within 2 months in patient 20. While INR markedly increased and levels of factor VII
(plasma half-life: 5 hours) and factor V (plasma half-life: 15 hours) decreased during hyperammonemia, all laboratory parameters normalized between
events. Albumin (plasma half-life 20 days) remained in the (lower) normal range during hyperammonemic episodes.
aaPTT, activated partial thromboplastin time
bClotting factors V and VII.
doi:10.1371/journal.pone.0153358.t003
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Taken together these laboratory data point towards a reduced hepatic synthesis of coagula-
tion factors, which occurs intermittently with (near) normalization between exacerbations.
As listed in Table 2, liver transaminases remained normal in some patients even during
severe liver involvement with massively elevated INR values and hyperammonemia. Levels of
liver transaminases varied among patients and ranged from (close to) normal to highly ele-
vated. As illustrated in patient 21.1 (Fig 3), INR increased early during metabolic decompensa-
tion, while liver transaminases remained normal during the entire episode. It is however likely
that a prolonged hepatocyte dysfunction in some patients eventually leads to hepatic cell death
thereby causing elevated liver transaminases.
Experimental evidence for ammonia-induced impairment of protein
synthesis
To validate the hypothesis that ammonia causes decreased hepatic protein synthesis, albumin
production and secretion were investigated in isolated human primary hepatocytes upon
NH4Cl treatment. While plasma albumin levels in patients commonly remain in the (low to)
normal range during short periods of hyperammonemia due to its long plasma half-life
(Table 3), in short-term cell culture studies of hyperammonemia, the suspected negative effect
of NH4Cl on the production rate of albumin can be quantified in the cell culture supernatant.
Albumin was chosen because it is robustly secreted and readily detectable in cell culture super-
natant of primary hepatocytes, whereas several coagulation factors are difficult to assess upon
short-term experiments due to very low concentrations [36].
First, we determined cell viability to exclude (unspecific) cell death under different NH4Cl
concentrations (0; 0.1; 1; 10 mM). Cell viability was not affected by treatment and remained
unchanged to controls (Fig 4A), confirming previous reports [37]. Albumin secretion revealed
a significant (p< 0.05, Student’s T-test) decrease upon treatment with 10 mMNH4Cl after 24
and 48 hours compared to controls (Fig 4B). Urea production was increased during treatment
with NH4Cl indicating a functioning urea cycle in these cells (Fig 4C). Quantification of ASAT
Table 4. Unresponsiveness to vitamin K in coagulopathy occurring in OTCD.
Laboratory parameters INR Quick
(%)
aPTT
(sec)
Fibrinogen (g/
L)
Factor V
(%)
Vitamin K-dependent hemostatic factors (%)
II VII IX X Prot.
C
Prot.
S
Normal Range <1.2 >70 25–36 1.75–3.75 78–153 68–
140
70–
139
79–
138
78–
144
71–
165
75–
141
outpatient visit 2.2 30 47.1 2.3 73 65 12 n.a. 48 n.a. n.a.
2d after oral intake of 5 mg
vit. K
2.2 31 41.1 2.4 61 73 11 26 49 11 69
before i.v. injection of 5 mg
vit. K
1.3 61 35.6 2.6 86 104 45 43 85 27 73
2d after i.v. injection of 5 mg
vit. K
1.5 46 36.5 2.4 85 97 27 37 80 23 78
Plasma half-lives 100h 15h 65h 5h 25h 40h 7h 43h
Table 4 shows laboratory evaluation of coagulation parameters including individual pro- and anticoagulant factors in patient 14.1 during an outpatient
routine control, 2 days (2d) after oral intake of 5 mg vitamin K (vit. K), and immediately before and 2d after intravenous (i.v.) application of 5 mg vit. K.
Neither of the two vit. K applications led to an increase of vitamin K-dependent factors (FII, VII, IX, X, protein C and S). Moreover, also the non-vitamin-K-
dependent factor V was reduced in the ﬁrst two blood examinations, thus suggesting an impaired synthetic function of the liver as reason for diminished
plasmatic coagulation factors and not a vitamin K deﬁciency.
doi:10.1371/journal.pone.0153358.t004
Acute Liver Failure in Ornithine Transcarbamylase Deficiency (OTCD)
PLOS ONE | DOI:10.1371/journal.pone.0153358 April 12, 2016 9 / 15
revealed a potential negative effect of ammonia on mitochondrial integrity as it increases over
time in the treated cells (Fig 4D).
Discussion
The effects of ammonia toxicity on the central nervous system have been intensely studied
using several in vitro and in vivomodels that suggested ammonia toxicity to the developing
brain by alteration of amino acid and neurotransmitter pathways, by interference with the tri-
carboxylic acid cycle, ATP production and concomitantly brain energy metabolism [38]. In
contrast, little is known about the effects of elevated ammonia on the hepatic system. A prime
example of the effect of hyperammonemia on liver function is the group of patients with pri-
mary acute hyperammonemia who develop ALF and concomitant coagulopathy as reported
Fig 3. INR is a sensitive parameter of ammonia-related liver dysfunction. Fig 3 illustrates laboratory values from patient 21.1 with neonatal onset of
OTCD causing acute liver failure (ALF) and fatal disease course. Concomitant with massive hyperammonemia (max. 2569 μmol/L; upper left y-axis in grey
colour), INR was drastically elevated (max. 4.1; lower left y-axis in red colour) while both liver transaminases (here only ALAT is shown; max. 25 U/L)
remained normal. After suspicion of OTCD, this patient immediately received specific treatment including hemodialysis resulting in rapid normalization of
plasma ammonia levels after two days of treatment. However, INR remained elevated despite application of fresh frozen plasma and the patient deceased
frommultiorgan failure.
doi:10.1371/journal.pone.0153358.g003
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previously [5–9], and as described here. Although previous reports have described UCD
patients with markedly increased INR/PT values during metabolic crises, thus reflecting ALF
[6, 11], the underlying pathophysiology is unclear. Uncovering the molecular mechanisms
Fig 4. Effects of NH4Cl exposure on human primary hepatocytes. Following treatment with NH4Cl, several parameters were determined in cell culture
supernatant: A, Cell viability showed no significant differences between various treatment groups (0; 0.1; 1; 10 mM NH4Cl for 24 h) compared to non-treated
control cells as assessed by MTT assay. B, Albumin secretion was quantified by ELISA. While control cells secreted 1944 ± 235 μg/L albumin in 24 hours,
cells treated with 10 mMNH4Cl secreted only 1471 ± 25 μg/L and after 48 hours controls secreted 2820 ± 464 μg/L versus 1666 ± 53 μg/L in treated cells.C,
Quantification of urea: while in untreated hepatocytes urea in supernatant increases slightly from 0.42 mmol/L at 24 h to 0.64 mmol/L at 48 h, in NH4Cl-
treated cells urea production increases from 0.82 mmol/L to 1.31 mmol/L, respectively. D,Quantification of ASAT reveals a potential negative effect of
ammonia on mitochondrial integrity.
doi:10.1371/journal.pone.0153358.g004
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leading to ALF may help tailor treatment decisions including the development of consensus
criteria for liver transplantation.
Analysis of our OTCD cohort revealed ALF as a very frequent complication with 100% of
male patients and 40% of symptomatic females being affected at least once during disease
course. This gender difference is most likely explained by the X-chromosomal inheritance of
OTCD, rendering (especially neonatal) male patients at a higher risk of metabolic decompensa-
tion with hyperammonemia and concomitant ALF. Our epidemiological data confirm the so
far only systematic clinical study of liver involvement in OTCD patients [6], and underlines
that hepatic complications of UCDs may be an underrecognized condition. Affected neonates
often suffer from multiorgan failure and may not survive the initial metabolic crisis. Concomi-
tant liver dysfunction may not be considered as a specific complication of OTCD, thus not
receiving enough attention, particularly during the emergency management of acute hyperam-
monemia. However, ALF may be a trigger of multiorgan failure and a rapid and targeted inter-
vention could prevent, at least in some patients, an often fatal disease course. Moreover, ALF
may be underrecognized because specific clinical symptoms such as severe bleeding may be
missing. Although several of our patients suffered from recurrent (laboratory) coagulopathy
with massively elevated INR values, bleeding complications did not belong to the characteristic
complications. The reason for the low incidence of bleeding may be the simultaneous
impairment of procoagulant and anticoagulant hemostatic factors (as demonstrated in Table 4
for patient 14.1), thereby mitigating the risk for hemorrhagic events [39, 40].
The main laboratory finding in our cohort is the close association of elevated INR values
with high plasma ammonia levels. This suggests a causative role of hyperammonemia in
impairing hepatic protein synthesis thus leading to a rapid reduction of short-lived plasma
coagulation factors. In fact, all patients in our cohort for whom data were available showed a
rapid decrease of coagulation factor VII in plasma and concomitantly an increase of INR con-
sistent with ALF as the cause of the coagulopathy. At the same time, in most neonatal patients
liver transaminases remained normal despite severe liver involvement. Taken together, these
laboratory data suggest an ammonia-induced inhibition of hepatic protein synthesis rather
than (unspecific) cell death as underlying mechanism of hyperammonemia-induced ALF.
In our cohort, we have two siblings (14.1 and 14.2) who suffered from RALF in whom we
observed pathological INR values even in the absence of hyperammonemia. We cannot con-
clude whether in certain patients, even slight (or intermittent) elevations of ammonia are suffi-
cient to cause ALF or whether there are other potential triggers causing ALF. It was previously
reported by others that coagulopathy rarely occurs in OTCD patients even in remission state in
absence of relevant hyperammonemia [10]. The authors speculated that a potential vitamin K
deficiency could be the reason for coagulopathy in affected patients. However, analysis of
serum des-γ-carboxyprothrombin (PIVKA-II, a marker of vitamin K deficiency) was normal
in 3 of 4 of their analyzed patients. In line with that, in none of our patients (as illustrated in
Table 4 for patient 14.1) we found a vitamin K response.
To further explore our hypothesis of ammonia-induced inhibition of hepatic protein syn-
thesis, we performed in vitro experiments using isolated primary hepatocytes from a non-
affected donor. First, cell culture studies showed a significantly reduced production rate of
albumin (the most abundant secreted hepatic protein) upon NH4Cl treatment. Next, when
applying up to 10 mmol/L NH4Cl we did not detect cytotoxicity but found a moderate increase
of ASAT, thus indicating a negative effect on mitochondrial integrity. This is in line with
recently published data of an inhibitory effect of ammonia on mitochondrial integrity in hepa-
tocytes in vitro when high concentrations of NH4Cl (20 mmol/L) induced an intrinsic Ca
2+-
independent apoptosis pathway [18].
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Although primary human hepatocytes are a useful tool to study effects of ammonia toxicity
on a molecular level, there are certain limitations. One major drawback of primary hepatocytes
is their lack of availability. Besides that, despite the enormous replication potential of hepato-
cytes in vivo they cannot serve as culture for long-term studies in vitro [41]. Moreover, while
we aim to investigate pathophysiological differences between “healthy” human primary hepa-
tocytes and UCD patient-derived hepatocytes in an in vitro system, access to UCD patient
hepatocytes is utmost challenging and very difficult to plan in advance.
In summary, ALF is a common complication of acute hyperammonemia in patients with
OTCD and was also reported in other UCDs such as citrullinemia type 1 [5, 13]. In an attempt
to better understand the underlying mechanisms, we found strong evidence that ammonia dis-
plays a direct toxic role on hepatic protein synthesis. However, while the association of hyper-
ammonemia and ALF is clear, the exact pathophysiological sequence may be even more
complicated although this is rather speculative. As a clinical consequence, we suggest adding
INR test in routine care of patients with liver dysfunction early during their work-up. Building
up on our findings, further studies of ALF in other UCDs and likewise in other conditions of
(secondary) hyperammonemia will shed light on the involved pathophysiological mechanisms
and will aid the decision on whether or not to perform urgent liver transplantation in ALF
and/or other therapeutic strategies.
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